January 29, 2015     Japanese 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business

Tokyo, Jan 22, 2013 (JCN) - Teijin Limited announced today that it has signed a strategic partnership agreement with InCube Labs, a California-based life science research lab, to accelerate Teijin's healthcare business development. Teijin will invest in a company affiliated with InCube Labs.

By leveraging its extensive network and expertise, InCube Labs will help Teijin to define strategic growth opportunities for its healthcare business. Initiatives will include competitive evaluation of Teijin technologies, analysis of key market characteristics and regulations, and provision of information to help Teijin identify promising business partners and M&A opportunities.

Healthcare is one of the growth drivers in the Teijin group's medium- to long-term management vision. The group plans to integrate its materials and healthcare technologies to facilitate its expansion into fields including regenerative medicine and tissue repair, drug delivery systems and locomotive syndrome.

"To help us expand our healthcare business and create solutions for unmet medical needs, we sought a partner with deep understanding of the healthcare market, including technologies and business opportunities," said Kazuo Imose, Teijin Group Corporate Officer and General Manager of the New Business Incubation and Development Division. "InCube Labs' extensive knowledge and track record in healthcare innovation and company formation, including in the fields of medical instruments and materials, will be a tremendous asset as we pursue opportunities in the healthcare domain."

About InCube Labs
Based in Silicon Valley and San Antonio, InCube Labs is a life sciences research lab focused on developing medical breakthroughs that dramatically improve patient outcomes. Its multi-disciplinary approach integrates traditional device technologies such as electronics, software, mechanical engineering and material science, with innovations from the pharmaceutical industry, often involving protein chemistry, pharmacology and cell biology.

By Chris Lui Staff Writer

Copyright © 2015 JCN. All rights reserved. A division of Japan Corporate News Network KK.

 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Teijin Group News  
  Teijin Opens Second Production Line for LIELSORT Separators for LIBs  (Dec 18, 2014)
  Teijin Begins OEM Production of New Phosphorus Flame Retardant  (Dec 11, 2014)
  Teijin Develops Printable Electronics Material for PV Cells with High Conversion Efficiency  (Oct 14, 2014)
  Teijin Develops Advanced Outerwear Fabric  (June 16, 2014)
  Teijin DuPont Films Develops World-class Flame-retardant Film  (Apr 8, 2014)
  Teijin Frontier to Establish New Company in Myanmar  (Sept 9, 2013)
  Teijin's Technora Para-aramid Fiber to be used in Space Elevator Challenge  (Aug 6, 2013)
  Teijin's High-performance Polyester used for High-quality Bedding by ANA  (Aug 2, 2013)
  Teijin Develops Eco-friendly Wet-strong Printing Paper  (Mar 12, 2013)
  Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping  (Feb 21, 2013)

 Recent  Medical News   
Otsuka Announces Termination of Contracts (Jan 8, 2015)
Otsuka: U.S. FDA Approves Labeling Update of Abilify Maintena (Aripiprazole) (Dec 8, 2014)
Otsuka Pharmaceutical to Launch L-Cartin FF Tablets for Carnitine Deficiencies in Japan (Dec 1, 2014)
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)

More Medical news...
CSR Report Download
Annual Reports

  More >>    
Most Popular

About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)